European Hematology Association (EHA) 2022
A Matching-Adjusted Indirect Comparison of the Efficacy of Pegcetacoplan using PRINCE Trial data versus Ravulizumab and Eculizumab in Complement-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria
A Real-World Analysis of Healthcare Resource Utilization Among Patients with Paroxysmal Nocturnal Hemoglobinuria Who Received Treatment with Ravulizumab
Categorizing Hematological Response to Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Post Hoc Analysis of the Phase 3 PRINCE Study Data
Normalization of Hematologic and QoL Markers in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan and Baseline Hemoglobin at or Above 10 g/dL
Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan Show Improvements in D-dimer Normalization and Decrease in Incidence of Thrombosis
Pegcetacoplan Rapidly Stabilizes Complement Inhibitor Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria Experiencing Hemolysis with Acute Hemoglobin Decreases: PRINCE Trial Post Hoc Analysis
Effect of Pegcetacoplan on Quality of Life in Complement-Inhibitor Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Phase 3 PRINCE Study
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.